Role of Self-medication in the Development of Comorbid Anxiety and Substance Use Disorders: a Longitudinal Investigation
Overview
Affiliations
Context: Self-medication of anxiety symptoms with alcohol, other drugs, or both has been a plausible mechanism for the co-occurrence of anxiety disorders and substance use disorders. However, owing to the cross-sectional nature of previous studies, it has remained unknown whether self-medication of anxiety symptoms is a risk factor for the development of incident substance use disorder or is a correlate of substance use.
Objective: To examine whether self-medication confers risk of comorbidity.
Design: A longitudinal, nationally representative survey was conducted by the National Institute on Alcohol Abuse and Alcoholism. The National Epidemiologic Survey on Alcohol and Related Conditions assessed DSM-IV psychiatric disorders, self-medication, and sociodemographic variables at 2 time points.
Setting: The United States.
Participants: A total of 34 653 US adults completed both waves of the survey. Wave 1 was conducted in 2001-2002, and wave 2 interviews occurred 3 years later (2004-2005).
Main Outcome Measures: Incident substance use disorders in participants with baseline anxiety disorders and incident anxiety disorders in those with baseline substance use disorders.
Results: Logistic regression analyses revealed that self-medication conferred a heightened risk of new-onset substance use disorders in those with baseline anxiety disorders (adjusted odds ratios [AORs], 2.50-4.99 [P < .01]). Self-medication was associated with an increased risk of social phobia (AOR in baseline alcohol use disorders, 2.13 [P = .004]; AOR in baseline drug use disorders, 3.17 [P = .001]).
Conclusions: Self-medication in anxiety disorders confers substantial risk of incident substance use disorders. Conversely, self-medication in substance use disorders is associated with incident social phobia. These results not only clarify several pathways that may lead to the development of comorbidity but also indicate at-risk populations and suggest potential points of intervention in the treatment of comorbidity.
Lerma A, Soto-Huerta J, Gonzalez-Flores C, Guzman-Saldana R, Aguirre-Villegas D, Lerma C Healthcare (Basel). 2025; 13(3).
PMID: 39942496 PMC: 11817057. DOI: 10.3390/healthcare13030307.
Lin E, Veenker F, Manza P, Yonga M, Abey S, Wang G Brain Sci. 2025; 14(12.
PMID: 39766484 PMC: 11674329. DOI: 10.3390/brainsci14121285.
Moretta P, Cavallo N, Candia C, Lanzillo A, Marcuccio G, Santangelo G J Clin Med. 2024; 13(21).
PMID: 39518558 PMC: 11546101. DOI: 10.3390/jcm13216418.
Tap S Addict Biol. 2024; 29(4):e13386.
PMID: 38600715 PMC: 11007263. DOI: 10.1111/adb.13386.
Melkam M, Demilew D, Kassew T, Fanta B, Yitayih S, Alemu K PLoS One. 2024; 19(3):e0300927.
PMID: 38512930 PMC: 10956842. DOI: 10.1371/journal.pone.0300927.